QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.094631v1 316/1/448    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Crudden, G. Articles by Craven, R. J. Search for Related Content PubMed PubMed Citation Articles by Crudden, G. Articles by Craven, R. J. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Medline Plus Health Information Cancer Cancer Chemotherapy Hazardous Substances DB DOXORUBICIN

CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Hpr6 (Heme-1 Domain Protein) Regulates the Susceptibility of Cancer Cells to Chemotherapeutic Drugs

Department of Molecular and Biomedical Pharmacology, Markey Cancer Center, University of Kentucky, Lexington, Kentucky

Cancer cells have varying levels of susceptibility to chemotherapeutic agents, and the proteins that direct drug susceptibility are promising targets for intervention in cancer. Hpr6 (heme-1 domain protein)/PGRMC1 (progesterone receptor membrane component 1) is overexpressed in tumors, and Hpr6 is the human homolog of a budding yeast damage resistance gene called Dap1p. Cells lacking Dap1p are damage-sensitive, and we have found that inhibition of Hpr6 expression by RNA inhibition (RNAi) increases sensitivity of breast cancer cells to chemotherapeutic drugs. Hpr6 is composed largely of a cytochrome b₅-related heme-1 domain, and we have found that purified Hpr6 binds to heme, similar to its yeast and rodent homologues. We generated an aspartate 120-to-glycine (D120G) mutant of Hpr6 at a highly conserved site in the heme-1 domain and demonstrated that Hpr6-D120G cannot bind to heme. The Hpr6-D120G mutant was named Hpr6^hbd for heme binding defective. We prepared an adenovirus encoding Hpr6^hbd and found that adenovirus Hpr6^hbd increases susceptibility of breast cancer cells to doxorubicin and camptothecin. Our findings support a model in which Hpr6, similar to its yeast homolog, binds to heme and regulates susceptibility to damaging agents.

Address correspondence to: Dr. Rolf J. Craven, Department of Molecular and Biomedical Pharmacology, Markey Cancer Center, MS-305 University of Kentucky Medical Center, Lexington, KY 40536-0298. E-mail: rolf.craven{at}uky.edu

This article has been cited by other articles:

				J. J. Peluso, A. Gawkowska, X. Liu, T. Shioda, and J. K. Pru Progesterone Receptor Membrane Component-1 Regulates the Development and Cisplatin Sensitivity of Human Ovarian Tumors in Athymic Nude Mice Endocrinology, November 1, 2009; 150(11): 4846 - 4854. [Abstract] [Full Text] [PDF]

				S. Glaser, S. DeMorrow, H. Francis, Y. Ueno, E. Gaudio, S. Vaculin, J. Venter, A. Franchitto, P. Onori, B. Vaculin, et al. Progesterone stimulates the proliferation of female and male cholangiocytes via autocrine/paracrine mechanisms Am J Physiol Gastrointest Liver Physiol, July 1, 2008; 295(1): G124 - G136. [Abstract] [Full Text] [PDF]

				J. J. Peluso, X. Liu, M. M. Saunders, K. P. Claffey, and K. Phoenix Regulation of Ovarian Cancer Cell Viability and Sensitivity to Cisplatin by Progesterone Receptor Membrane Component-1 J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1592 - 1599. [Abstract] [Full Text] [PDF]

				J. J. Peluso, J. Romak, and X. Liu Progesterone Receptor Membrane Component-1 (PGRMC1) Is the Mediator of Progesterone's Antiapoptotic Action in Spontaneously Immortalized Granulosa Cells As Revealed by PGRMC1 Small Interfering Ribonucleic Acid Treatment and Functional Analysis of PGRMC1 Mutations Endocrinology, February 1, 2008; 149(2): 534 - 543. [Abstract] [Full Text] [PDF]

				R. J. Craven, J. C. Mallory, and R. A. Hand Regulation of Iron Homeostasis Mediated by the Heme-binding Protein Dap1 (Damage Resistance Protein 1) via the P450 Protein Erg11/Cyp51 J. Biol. Chem., December 14, 2007; 282(50): 36543 - 36551. [Abstract] [Full Text] [PDF]